| abstract |
The present invention relates to a monoclonal antibody directed against the human LDL (Low Density Lipoprotein) receptor, binding to the peptide corresponding to amino acids 195-222 (SEQ ID NO: 1) of the peptide sequence of the LDL receptor, its use as a drug, a pharmaceutical composition containing this antibody, as well as its use in immunohistochemical analysis of cancerous, healthy or cirrhoidal tissues, in Western blot, in ELISA or in in vivo quantification test. |